Clinical trial · Interventional
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
Implementation of a Therapeutic Educational Program Applicated to Adherence of Patients Treated by Capecitabine Alone or in Combination With Lapatinib
NCT01847599CI-TRIAL-00028717ProMETheXterminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): interim analysis : discontinuation for efficacy of the intervention
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- capecitabine
- description
- patients treated by capecitabine alone (n=100)
- interventionNames
- Other: Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib
- type
- OTHER
- label
- capecitabine + lapatinib
- description
- patients treated by capecitabine and lapatinib (n=100)
- interventionNames
- Other: Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib
Primary outcomes (1)
- measure
- evaluation of the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age\> 18 years * histologically confirmed breast cancer or colorectal cancer * Patient starting oral treatment : capecitabine alone or in combination with lapatinib (can be included before the first cycle or during the first 2 cycles). * Volunteer to participate in the study. * ambulatory treated patient * Able to read, write and understand French. * Subject who accept to use MEMS monitors to automatically compile their drug dosing histories * Written informed consent Exclusion Criteria: * more than 3 metastatic chemotherapies * any severe concomitant condition which makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol
References
Publications (0)
Data not yet available
No reference posted for this study.